Drugs / MVT-2163
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04883775 | May 2021 → Jan 2025 | malignant pancreatic neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02687230 | Jul 2016 → May 2017 | pancreatic adenocarcinoma | BioNTech SE | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVT-2163 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04883775 ↗ |
| Modality | Diagnostic / imaging agent | “MVT-2163 is administered intravenously as a PET imaging agent” NCT02687230 ↗ |
| Route | Intravenous | “MVT-2163 is administered intravenously as a PET imaging agent” NCT02687230 ↗ |